A phase II study of temozolomide (TMZ) and pegylated interferon α-2b (PGI) in the treatment of advanced melanoma
Susan E. Krown(Memorial Sloan Kettering Cancer Center), Jedd D. Wolchok(Cornell University), Lynne Lamb(Memorial Sloan Kettering Cancer Center), Wen-Jen Hwu(The University of Texas MD Anderson Cancer Center), Suzan Aird(Memorial Sloan Kettering Cancer Center), Linda Williams(Edinburgh Cancer Research), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Katherine S. Panageas(Mayo Clinic), P O Livingston(Memorial Sloan Kettering Cancer Center), Jennifer H. Menell
Cited by 2
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k